SCHEMBL16856983

SCHEMBL16856983

CCOC(=O)c1c(F)cncc1N=[N+]=[N-]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
PDE4D Q08499 1/20 0.35
NAMPT P43490 1/20 0.34
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 3/20 0.33
HPGD P15428 3/20 0.33
NPC1 O15118 3/20 0.33
GAA P10253 2/20 0.33
LMNA P02545 2/20 0.33
RAB9A P51151 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10464538 0.81 CYP2C9 (0.50) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL844441 0.75 CYP2C9 (0.45) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL844633 0.74 CYP2C9 (0.44) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL30950268 0.74 CYP2C9 (0.44) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL13067195 0.74 CYP2C9 (0.44) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL27601688 0.72 TSHR (0.40) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL16857302 0.71 ALDH1A1 (0.48) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL19718276 0.71 ESR1 (0.44) CA12CA1CA2CA7CA9
SCHEMBL18987673 0.69 MAOB (0.45) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL16857349 0.69 KDM4E (0.41) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150299188-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-22 US disclosed
EP-2889291-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299188-A1 HETEROCYCLIC COMPOUND PTGIS, LIPG, FEN1 CYP2C9 3766/4885CYP2C19 2518/4885CA12 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.